Long-Term Use of Dupilumab in Atopic Dermatitis

Ma Ling; Cai Tao

doi:10.23977/medsc.2024.050526

Long-Term Use of Dupilumab in Atopic Dermatitis

Download as PDF

DOI: 10.23977/medsc.2024.050526 | Downloads: 9 | Views: 518

Author(s)

Ma Ling ¹, Cai Tao ¹

Affiliation(s)

¹ Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China

Corresponding Author

Cai Tao

ABSTRACT

Dupilumab, a fully human monoclonal antibody targeting IL-4Rα, has shown significant efficacy in the treatment of moderate to severe atopic dermatitis (AD). However, comprehensive analysis of its long-term use remains limited. This review evaluates the long-term efficacy, safety and treatment strategies of dupilumab to help clinicians develop personalised treatment plans for AD patients. Long-term studies and real-world evidence show that dupilumab maintains its therapeutic effect for up to five years, with most patients achieving sustained remission. The safety profile is generally favourable, with most adverse events being mild or moderate and reversible. As treatment duration increases, extending the dosing interval becomes an effective management strategy, particularly in patients with well-controlled disease. This approach improves patient compliance, reduces treatment costs and maintains efficacy. Based on current evidence, it is recommended to initially extend the dosing interval to every 3-4 weeks.

KEYWORDS

Dupilumab, Atopic Dermatitis (AD), Long-term Efficacy, Treatment Strategy, Dosing Interval Extension

CITE THIS PAPER

Ma Ling, Cai Tao. Long-Term Use of Dupilumab in Atopic Dermatitis. MEDS Clinical Medicine (2024) Vol. 5: 199-204. DOI: http://dx.doi.org/10.23977/medsc.2024.050526.

REFERENCES

[1] Bylund S, Kobyletzki LB, Svalstedt M, Svensson A. Prevalence and Incidence of Atopic Dermatitis: A Systematic Review. Acta Derm Venereol. 2020;100(12):adv00160.
[2] Abuabara K, Margolis DJ, Langan SM. The Long-Term Course of Atopic Dermatitis. Dermatol Clin. 2017;35(3):291-307.
[3] Brunner PM, Guttman-Yassky E, Leung DY. The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies. J Allergy Clin Immunol. 2017;139(4S):S65-S76.
[4] Gandhi NA, Bennett BL, Graham NM, Pirozzi G, Stahl N, Yancopoulos GD. Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov. 2016;15(1):35-50.
[5] Del Rosso JQ. MONOCLONAL ANTIBODY THERAPIES for Atopic Dermatitis: Where Are We Now in the Spectrum of Disease Management? J Clin Aesthet Dermatol. 2019;12(2):39-41.
[6] Vittrup I, Krogh NS, Larsen HHP, Elberling J, Skov L, Ibler KS, et al. A nationwide 104 weeks real-world study of dupilumab in adults with atopic dermatitis: Ineffectiveness in head-and-neck dermatitis. J Eur Acad Dermatol Venereol. 2023;37(5):1046-1055.
[7] Harb H, Chatila TA. Mechanisms of Dupilumab. Clin Exp Allergy. 2020;50(1):5-14.
[8] Nelms K, Keegan AD, Zamorano J, Ryan JJ, Paul WE. The IL-4 receptor: signaling mechanisms and biologic functions. Annu Rev Immunol. 1999;17:701-738.
[9] Chiaramonte MG, Mentink-Kane M, Jacobson BA, Cheever AW, Whitters MJ, Goad ME, et al. Regulation and function of the interleukin 13 receptor alpha 2 during a T helper cell type 2-dominant immune response. J Exp Med. 2003;197(6):687-701.
[10] Wood N, Whitters MJ, Jacobson BA, Witek J, Sypek JP, Kasaian M, et al. Enhanced interleukin (IL)-13 responses in mice lacking IL-13 receptor alpha 2. J Exp Med. 2003;197(6):703-719.
[11] Le Floc'h A, Allinne J, Nagashima K, Scott G, Birchard D, Asrat S, et al. Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4Ralpha antibody, is required to broadly inhibit type 2 inflammation. Allergy. 2020;75(5):1188-1204.
[12] McCann MR, Kosloski MP, Xu C, Davis JD, Kamal MA. Dupilumab: Mechanism of action, clinical, and translational science. Clin Transl Sci. 2024;17(8):e13899.
[13] Dekkers C, van der Wal MM, van den Noort L, Bakker DS, de Bruin-Weller M, van Wijk F. IgE levels in patients with atopic dermatitis steadily decrease during treatment with dupilumab regardless of dose interval. Clin Exp Allergy. 2023;53(11):1222-1235.
[14] Dekkers C, der Wal MMV, El Amrani M, Luin MV, Bakker DS, Bruin-Weller M, et al. Biological Tipping Point in Patients with Atopic Dermatitis Treated with Different Dosing Intervals of Dupilumab. J Invest Dermatol. 2023;143(9):1822-1833.
[15] Beck LA, Bissonnette R, Deleuran M, Nakahara T, Galus R, Coleman A, et al. Dupilumab in Adults With Moderate to Severe Atopic Dermatitis: A 5-Year Open-Label Extension Study. JAMA Dermatol. 2024;160(8):805-812.
[16] Barei F, Calzari P, Valtellini L, Chiei Gallo A, Perego G, Tavecchio S, et al. Five-year real-world drug survival of dupilumab in severe atopic dermatitis and associate predictors. J Dermatolog Treat. 2024;35(1):2404718.
[17] Boesjes CM, Kamphuis E, de Graaf M, Spekhorst LS, Haeck I, van der Gang LF, et al. Long-Term Effectiveness and Reasons for Discontinuation of Dupilumab in Patients With Atopic Dermatitis. JAMA Dermatol. 2024;160(10):1044-1055.
[18] Paller AS, Siegfried EC, Simpson EL, Cork MJ, Sidbury R, Chen IH, et al. Dupilumab Safety and Efficacy up to 1 Year in Children Aged 6 Months to 5 Years with Atopic Dermatitis: Results from a Phase 3 Open-Label Extension Study. Am J Clin Dermatol. 2024;25(4):655-668.
[19] Pagan AD, David E, Ungar B, Ghalili S, He H, Guttman-Yassky E. Dupilumab Improves Clinical Scores in Children and Adolescents With Moderate to Severe Atopic Dermatitis: A Real-World, Single-Center Study. J Allergy Clin Immunol Pract. 2022;10(9):2378-2385.
[20] Wang Y, Jia R, Hu Q, Tao X, He Q, Luo G, et al. Long-term efficacy and safety of dupilumab for moderate-to-severe atopic dermatitis: a prospective real-world cohort study in China. Front Immunol. 2024;15:1419164.
[21] Zhou X, Yang G, Chen X, Zhang L. Efficacy and Safety of Dupilumab in Older Patients (Aged 80 Years and Above) with Atopic Dermatitis: A Prospective Study. Drugs Aging. 2023;40(10):933-940.
[22] Deng S, Wang H, Chen Q, Chen X, Song X, Chen S, et al. Long-term, observational, real-world study of dupilumab for the treatment of moderate-to-severe atopic dermatitis: a 52-week single-center retrospective analysis in China. Arch Dermatol Res. 2024;316(6):304.
[23] Spekhorst LS, Bakker D, Drylewicz J, Rispens T, Loeff F, Boesjes CM, et al. Patient-centered dupilumab dosing regimen leads to successful dose reduction in persistently controlled atopic dermatitis. Allergy. 2022;77(11):3398-3407.
[24] Spekhorst LS, Boesjes CM, Loman L, Zuithoff NPA, Bakker DS, Kamphuis E, et al. Successful tapering of dupilumab in patients with atopic dermatitis with low disease activity: a large pragmatic daily practice study from the BioDay registry. Br J Dermatol. 2023;189(3):327-345.
[25] Tilotta G, Bongiorno MR. Lengthening the time intervals between doses of dupilumab in remission atopic dermatitis. J Eur Acad Dermatol Venereol. 2023.
[26] Jendoubi F, Shourik J, Seneschal J, Giordano-Labadie F, Raison-Peyron N, Du-Thanh A, et al. Longer dupilumab dosing intervals in adult patients with atopic dermatitis: experience from a French multicentre retrospective cohort study. Br J Dermatol. 2022;187(4):602-613.
[27] Sanchez-Garcia V, Navarro-Trivino FJ, Silvestre JF. Evaluation of dupilumab dosing regimen in patients with persistently controlled atopic dermatitis. J Eur Acad Dermatol Venereol. 2023;37(12):e1426-e1439.
[28] Mastorino L, Gelato F, Richiardi I, Cavaliere G, Quaglino P, Ortoncelli M, et al. Dose reduction of dupilumab in atopic patients with controlled atopic dermatitis: A safe and effective practice? J Eur Acad Dermatol Venereol. 2023;37(5):e691-e702.
[29] Su Z, Zeng YP. Dupilumab-associated psoriasis and psoriasiform manifestations: a scoping review. Dermatology. 2023;239(4):646-657.

Subscription

E-Mail Alert

Downloads:	8502
Visits:	498362

Long-Term Use of Dupilumab in Atopic Dermatitis

Author(s)

Affiliation(s)

Corresponding Author

ABSTRACT

KEYWORDS

CITE THIS PAPER

REFERENCES

RESOURCES

JOIN US

PUBLICATION SERVICES

CONTACT US